128 related articles for article (PubMed ID: 36326203)
1. Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting.
De Leo S; Trevisan M; Colombo C; Moneta C; Giancola N; Fugazzola L
Thyroid; 2023 Jan; 33(1):74-81. PubMed ID: 36326203
[No Abstract] [Full Text] [Related]
2. Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm.
Colombo C; Ceruti D; De Leo S; Bilo G; Trevisan M; Giancola N; Moneta C; Parati G; Persani L; Fugazzola L
Eur Thyroid J; 2023 Jul; 12(4):. PubMed ID: 37097040
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib-induced hypocalcaemia due to transient primary hypoparathyroidism.
Trevisan M; Colombo C; Giancola N; Moneta C; Dionigi G; Fugazzola L; De Leo S
Endocrine; 2022 Oct; 78(1):197-200. PubMed ID: 35857272
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
De Leo S; Di Stefano M; Persani L; Fugazzola L; Colombo C
Endocrine; 2021 May; 72(2):462-469. PubMed ID: 32885329
[TBL] [Abstract][Full Text] [Related]
5. Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution.
Porcelli T; Luongo C; Sessa F; Klain M; Masone S; Troncone G; Bellevicine C; Schlumberger M; Salvatore D
Endocrine; 2021 Aug; 73(2):358-366. PubMed ID: 33537956
[TBL] [Abstract][Full Text] [Related]
6. The utility of intact parathyroid hormone level in managing hypocalcemia after thyroidectomy in children.
Jiang W; Lee E; Newfield RS
Int J Pediatr Otorhinolaryngol; 2019 Oct; 125():153-158. PubMed ID: 31323353
[TBL] [Abstract][Full Text] [Related]
7. Normal parathyroid hormone levels do not exclude permanent hypoparathyroidism after thyroidectomy.
Promberger R; Ott J; Kober F; Karik M; Freissmuth M; Hermann M
Thyroid; 2011 Feb; 21(2):145-50. PubMed ID: 21190447
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
10. The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity.
Masaki C; Shioya J; Sugino K; Terasawa Y; Yokotsuka S; Nakata M; Kitagawa W; Ito K
Support Care Cancer; 2023 Nov; 31(12):729. PubMed ID: 38017341
[TBL] [Abstract][Full Text] [Related]
11. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Ye X; Zhu Y; Cai J
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
[No Abstract] [Full Text] [Related]
13. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer.
Giani C; Valerio L; Bongiovanni A; Durante C; Grani G; Ibrahim T; Mariotti S; Massa M; Pani F; Pellegriti G; Porcelli T; Salvatore D; Tavarelli M; Torlontano M; Locati L; Molinaro E; Elisei R
Thyroid; 2021 Feb; 31(2):224-232. PubMed ID: 32907501
[No Abstract] [Full Text] [Related]
14. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma.
Ito Y; Onoda N; Kudo T; Masuoka H; Higashiyama T; Kihara M; Miya A; Miyauchi A
In Vivo; 2021; 35(2):1057-1064. PubMed ID: 33622902
[TBL] [Abstract][Full Text] [Related]
16. Perioperative parathyroid hormone assay for diagnosis and management of postthyroidectomy hypocalcemia.
Scurry WC; Beus KS; Hollenbeak CS; Stack BC
Laryngoscope; 2005 Aug; 115(8):1362-6. PubMed ID: 16094105
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib-induced renal failure: two first-time case reports and review of literature.
Cavalieri S; Cosmai L; Genderini A; Nebuloni M; Tosoni A; Favales F; Pistillo P; Bergamini C; Bossi P; Licitra L; Locati LD; Alfieri S
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):379-385. PubMed ID: 29617171
[TBL] [Abstract][Full Text] [Related]
18. Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina.
Jerkovich F; Califano I; Bueno F; Carrera JM; Giglio R; Abelleira E; Pitoia F
Endocrine; 2020 Jul; 69(1):142-148. PubMed ID: 32253682
[TBL] [Abstract][Full Text] [Related]
19. Effect of rate of calcium reduction and a hypocalcemic clamp on parathyroid hormone secretion: a study in dogs.
Estepa JC; Aguilera-Tejero E; Almaden Y; Rodriguez M; Felsenfeld AJ
Kidney Int; 1999 May; 55(5):1724-33. PubMed ID: 10231434
[TBL] [Abstract][Full Text] [Related]
20. Post-thyroidectomy hypocalcemia is related to parathyroid dysfunction even in patients with normal parathyroid hormone concentrations early after surgery.
Raffaelli M; De Crea C; D'Amato G; Moscato U; Bellantone C; Carrozza C; Lombardi CP
Surgery; 2016 Jan; 159(1):78-84. PubMed ID: 26456131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]